Compare FENC & ITHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FENC | ITHA |
|---|---|---|
| Founded | 1996 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.4M | 303.4M |
| IPO Year | 2010 | N/A |
| Metric | FENC | ITHA |
|---|---|---|
| Price | $7.44 | $9.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 120.6K | 45.7K |
| Earning Date | 03-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,538,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.69 | N/A |
| 52 Week Low | $4.68 | $9.87 |
| 52 Week High | $9.92 | $9.96 |
| Indicator | FENC | ITHA |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | 51.30 |
| Support Level | $7.44 | N/A |
| Resistance Level | $8.19 | $9.91 |
| Average True Range (ATR) | 0.43 | 0.00 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 11.79 | 25.00 |
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
ITHAX Acquisition Corp III is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.